Finkelstein F O, Goffinet J A, Hendler E D, Lindenbaum J
Am J Med. 1975 Apr;58(4):525-31. doi: 10.1016/0002-9343(75)90126-6.
The pharmacokinetics of digoxin and digitoxin in patients undergoing long-term hemodialysis were examined to determine which is the preferred cardiac glycoside in this patient population. Absorption curves from 0 to 24 hours after an oral dose of digitoxin were similar in dialyzed patients and in control patients. Serum glycoside concentrations after an oral dose of digoxin were higher in dialyzed patients than in control patients, significantly so from 2 to 24 hours, reflecting the absence of the predominantly renal route of excretion of digoxin. When nine dialyzed patients were placed on a maintenance dose of digoxin, 0.125 mg 5 days a week, serum levels plateaued at 30 days at a mean concentration (plus or minus SE) of 0.84 plus or minus 0.05 ng/ml. Maintenance therapy with 0.1 mg digitoxin 5 days a week resulted in stabilization of serum levels within 30 days at a mean concentration of 19 plus or minus 1 ng/ml. Variability in the serum glycoside concentrations was determined after stabilization of levels during 2 to 19 week follow-up periods with each drug. Variability in serum levels was somewhat increased during maintenance therapy with digitoxin. On the basis of the parmacokinetic data obtained in this study, no clear cut preference for one glycoside over the other could be established.
对长期接受血液透析的患者体内地高辛和洋地黄毒苷的药代动力学进行了研究,以确定在该患者群体中哪种强心苷更为适用。透析患者和对照患者口服洋地黄毒苷后0至24小时的吸收曲线相似。透析患者口服地高辛后的血清苷浓度高于对照患者,在2至24小时时差异显著,这反映了地高辛主要经肾脏排泄的途径缺失。当9名透析患者接受地高辛维持剂量治疗,每周5天,每天0.125毫克时,血清水平在30天时达到平稳,平均浓度(±标准误)为0.84±0.05纳克/毫升。每周5天,每天0.1毫克洋地黄毒苷的维持治疗导致血清水平在30天内稳定在平均浓度19±1纳克/毫升。在使用每种药物进行2至19周的随访期内,血清苷水平稳定后,测定了血清苷浓度的变异性。在使用洋地黄毒苷维持治疗期间,血清水平的变异性有所增加。基于本研究获得的药代动力学数据,无法明确确定对一种苷类相对于另一种苷类的偏好。